Seoul Asan Medical Center said it started prescribing the early Alzheimer's disease drug "Leqembi" (generic name lecanemab) on the 16th. "Leqembi" is a new treatment for Alzheimer's disease ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into ... the brain making it possible to reach deeper brain structures. A fast blood-brain barrier transport results ...

China Approves Kisunla as a New Alzheimer's Treatment Option After Eisai and Biogen's Leqembi were approved in January, Eli Lilly said late Tuesday that their treatment for early Alzheimer's has ...

17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend approval for Biogen's drug, Leqembi, in paragraph 8) China is the fourth major market ...

Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space ... Neomorph has now identified additional structures within proteins that can be targeted, ...

Shanghai Engineering Research Center of Molecular Therapeutics & New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

Non-Commercial (NC): Only non-commercial uses of the work are permitted. A method of assigning formal charges from counting “attachments” for visual inspection is introduced as part of the iterative ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like ...

TOKYO and CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...

(Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal ...